{"prompt": "['EudraCT Number 2019-002880-82, IRAS Number 1003208', '21. Appendixes', 'Appendix 1 - Studies of gut metabolites show conversion of UDCA to lithocholic', 'acid (LCA), a potent TGR5 ligand.', 'Our data suggest that UDCA treatment causes enrichment with bile salt hydrolase-', 'encoding bacteria of the Bacteroidetes phylum (Figure 1A). These deconjugate intestinal', 'bile acids, enabling their modification to the secondary bile acids; in particular UDCA is', 'converted to lithocholic acid (LCA). Of relevance to this application, secondary bile acids', 'have greater affinity for the bile acid receptor TGR5 (also known as G protein bile acid', 'receptor, GPBAR1), with LCA having the highest affinity37 Activation of TGR5 in the', 'intestine stimulates the release of GLP-1. Our pilot data also reveal increased', 'concentrations of LCA in the faeces of UDCA treated women (Figure 1B).', '****', '15000', 'A', 'B', 'ICP untreated', '100%', '10000', 'ICP on UDCA', '5000', '80%', 'Actinobacteria', '2000', 'Cyanobacteria', '1500', '60%', 'Tenericutes', '1000', 'Lentisphaerae', '40%', 'Other', '500', 'Proteobacteria', '20%', '50', 'Firmicutes', '40', '30', 'Bacteroidetes', '20', '10', '0%', '0', 'Normal', 'ICP no', 'ICP on UDCA', 'pregnancy', 'treatment', 'Figure 1. UDCA treatment alters the gut microbiota in ICP women. A. The ratio of Bacteroidetes', 'to Firmicutes is increased with UDCA treatment of ICP, determined by 16S rRNA sequencing of', 'the faecal microbiota. B. Secondary bile acids (LCA: lithocholic acid and UDCA) are significantly', 'elevated in the faeces of women with ICP who were taking UDCA. C. The dyslipidaemia of', 'cholestatic pregnancy is attenuated for cholesterol and low density lipoprotein (LDL) cholesterol', \"with UDCA treatment. Groups compared with 2-way ANOVA and Tukey's multiple comparisons\", 'tests, *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001.', 'Appendix 2 - UDCA treatment improves ICP-associated maternal and fetal', 'dyslipidaemia', '(Figure 2A). Importantly, we also show that maternal UDCA treatment is associated', 'with improvements in neonatal dyslipidaemia (Figure 2B).', 'GUARD protocol V1.0 11Mar20', 'Page 50 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', 'A', 'Maternal Serum', '12', 'Normal pregnancy', '10', 'ICP untreated', 'ICP on UDCA', '8', '6', '1', '4', 'I', 'T', 'T', '2', '0', 'hot', 'you', 'Fetal Serum', 'B', 'C', 'D', 'Female', 'Cholesterol', '0.2', 'TG', '2.000', 'Male', '0.2', 'FFA', 'T', '1.000', 'T', '0.1', 'T', '0.1', 'T', 'T', '0.000', 'o', '0', 'Control', 'ICP', 'ICP+UDCA', 'Control', 'ICP', 'ICP+UDCA', 'Control', 'ICP', 'ICP+UDCA', 'Figure 2. Impact of maternal UDCA treatment on fetal lipid profiles of women with ICP. A. Maternal', 'serum lipid profile of cholesterol, HDL-Cholesterol (HDL), LDL-Cholesterol (LDL), and triglycerides', 'in normal pregnancy, untreated ICP pregnancy, and UDCA-treated ICP pregnancy. Fetal lipid', 'profiles from mothers who had a normal pregnancy, ICP, or ICP treated with UDCA, of B.', 'Cholesterol, C. free fatty acids (FFA) and D. triglycerides (TG). Samples were measured from', 'umbilical cord serum in female and male fetuses of women with ICP. Error bars represent standard', 'error of the mean (SEM). Data were analysed by multiple measures of ANOVA followed by Neuman', \"Keul's post-hoc testing. *P<0.05, n=8-10.\", 'GUARD protocol V1.0 11Mar20', 'Page 51 of 53']\n\n###\n\n", "completion": "END"}